Single-Pass Intestinal Perfusion (SPIP) and prediction of fraction absorbed and permeability in humans: A study with antiretroviral drugs

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 104, Issue , 2016, Pages 131-139

  Dezani, Thaisa Marinho ^a   Dezani, André Bersani ^a   Junior, João Batista Da Silva ^a   Serra, Cristina Helena Dos Reis ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Drug transport; Fraction absorbed; Intestinal absorption; Paracellular transport; Passive diffusion transport; Permeability

Indexed keywords

FLUORESCEIN; LAMIVUDINE; METOPROLOL; STAVUDINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APPARENT PERMEABILITY; ARTICLE; CONTROLLED STUDY; DRUG PENETRATION; FRACTION ABSORBED; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; INTESTINE PERFUSION; MALE; NONHUMAN; PREDICTION; RAT; SINGLE PASS INTESTINE PERFUSION; PERMEABILITY;

ANTI-RETROVIRAL AGENTS; HUMANS; PERMEABILITY;

EID: 84966365413     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2016.04.020     Document Type: Article

References (75)

1. P.V. Balimane, S. Chong, and R.a. Morrison Current methodologies used for evaluation of intestinal permeability and absorption J. Pharmacol. Toxicol. Methods 44 2000 301 312 10.1016/S1056-8719(00)00113-1
2. G.L. Amidon, H. Lennernäs, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420 10.1023/A:1016212804288
3. CDER/FDA Guidance for industry waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system Cent. Drug Eval. Res. 2000 < http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm128219.htm >
4. H. Lennernäs Animal data: the contributions of the ussing chamber and perfusion systems to predicting human oral drug delivery in vivo Adv. Drug Deliv. Rev. 59 2007 1103 1120 10.1016/j.addr.2007.06.016
5. M.N. Martinez, and G.L. Amidon A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals J. Clin. Pharmacol. 42 2002 620 643 10.1177/00970002042006005
6. C.Y. Wu, and L.Z. Benet Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm. Res. 22 2005 11 23 10.1007/s11095-004-9004-4
7. A. Dahan, B.T. West, and G.L. Amidon Segmental-dependent membrane permeability along the intestine following oral drug administration: evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat Eur. J. Pharm. Sci. 36 2009 320 329 10.1016/j.ejps.2008.10.013
8. L.S. Schanker, D.J. Tocco, B.B. Brodie, and C.a. Hogben Absorption of drugs from the rat small intestine J. Pharmacol. Exp. Ther. 123 1958 81 88
9. I. Lozoya-Agullo, M. Zur, O. Wolk, A. Beig, I. González-Álvarez, M. González-Álvarez, and et al. In-situ intestinal rat perfusions for human Fabs prediction and BCS permeability class determination: investigation of the single-pass vs. the Doluisio experimental approaches Int. J. Pharm. 480 2015 1 7 10.1016/j.ijpharm.2015.01.014
10. P. Zakeri-Milani, M. Barzegar-Jalali, M. Azimi, and H. Valizadeh Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability Eur. J. Pharm. Biopharm. 73 2009 102 106 10.1016/j.ejpb.2009.04.015
11. Z. Luo, Y. Liu, B. Zhao, M. Tang, H. Dong, L. Zhang, and et al. Ex vivo and in situ approaches used to study intestinal absorption J. Pharmacol. Toxicol. Methods 68 2013 208 216 10.1016/j.vascn.2013.06.001
12. S.C. Sutton, M.T. Rinaldi, and K.E. Vukovinsky Comparison of the gravimetric, phenol red, and 14C-PEG-3350 methods to determine water absorption in the rat single-pass intestinal perfusion model AAPS PharmSci 3 2001 E25 10.1208/ps030325
13. D.A. Volpe Application of method suitability for drug permeability classification AAPS J. 12 2010 670 678 10.1208/s12248-010-9227-8
14. U. Fagerholm, M. Johansson, and H. Lennernäs Comparison between permeability coefficients in rat and human jejunum Pharm. Res. 13 1996 1336 1342 10.1023/A:1016065715308
15. L. Salphati, K. Childers, L. Pan, K. Tsutsui, and L. Takahashi Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man J. Pharm. Pharmacol. 53 2001 1007 1013 10.1211/0022357011776252
16. H. Lennernäs Human jejunal effective permeability and its correlation with preclinical drug absorption models J. Pharm. Pharmacol. 49 1997 627 638 10.1111/j.2042-7158.1997.tb06084.x
17. P. Zakeri-Milani, H. Valizadeh, H. Tajerzadeh, Y. Azarmi, Z. Islambolchilar, S. Barzegar, and et al. Predicting human intestinal permeability using single-pass intestinal perfusion to rat J. Pharm. Pharm. Sci. 10 2007 368 379
18. X.Y. Chu, G.P. Sánchez-Castaño, K. Higaki, D.M. Oh, C.P. Hsu, and G.L. Amidon Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter J. Pharmacol. Exp. Ther. 299 2001 575 582
19. G.L. Amidon, P.J. Sinko, and D. Fleisher Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds Pharm. Res. 5 1988 651 654 10.1023/A:1015927004752
20. X. Cao, S.T. Gibbs, L. Fang, H.a. Miller, C.P. Landowski, H.C. Shin, and et al. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model Pharm. Res. 23 2006 1675 1686 10.1007/s11095-006-9041-2
21. R. Jain, S. Duvvuri, V. Kansara, N.K. Mandava, and A.K. Mitra Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats Int. J. Pharm. 336 2007 233 240 10.1016/j.ijpharm.2006.11.058
22. A.H. Eriksson, M.V.S. Varma, E.J. Perkins, and C.L. Zimmerman The intestinal absorption of a prodrug of the mGlu2/3 receptor agonist LY354740 is mediated by PEPT1: in situ rat intestinal perfusion studies J. Pharm. Sci. 99 2010 1574 1581 10.1002/jps.21917
23. R. Rathore, J.P. Jain, A. Srivastava, S.M. Jachak, and N. Kumar Simultaneous determination of hydrazinocurcumin and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation J. Pharm. Biomed. Anal. 46 2008 374 380 10.1016/j.jpba.2007.09.019
24. J.M. Reis, A.B. Dezani, T.M. Pereira, A. Avdeef, and C.H.R. Serra Lamivudine permeability study: a comparison between PAMPA, ex vivo and in situ Single-Pass Intestinal Perfusion (SPIP) in rat jejunum Eur. J. Pharm. Sci. 48 2013 781 789 10.1016/j.ejps.2012.12.025
25. S. Berggren, J. Hoogstraate, U. Fagerholm, and H. Lennernäs Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models Eur. J. Pharm. Sci. 21 2004 553 560 10.1016/j.ejps.2003.12.004
26. AVMA, AVMA guidelines on euthanasia: formerly report of the AVMA panel on euthanasia, 2013. doi: http://dx.doi.org/10.1007/s11634-008-0026-3.
27. K. Sugano, H. Hamada, M. Machida, H. Ushio, K. Saitoh, and K. Terada Optimized conditions of bio-mimetic artificial membrane permeation assay Int. J. Pharm. 228 2001 181 188 10.1016/S0378-5173(01)00845-6
28. E. Escribano, X.G. Sala, J. Salamanca, C.R. Navarro, and J.Q. Regué Single-pass intestinal perfusion to establish the intestinal permeability of model drugs in mouse Int. J. Pharm. 436 2012 472 477 10.1016/j.ijpharm.2012.07.010
29. S. Miret, L. Abrahamse, and E.M. de Groene Comparison of in vitro models for the prediction of compound absorption across the human intestinal mucosa J. Biomol. Screen. Off. J. Soc. Biomol. Screen. 9 2004 598 606 10.1177/1087057104267162
30. A.B. Dezani, T.M. Pereira, A.M. Caffaro, J.M. Reis, and C.H.D.R. Serra Determination of lamivudine and zidovudine permeability using a different ex vivo method in Franz cells J. Pharmacol. Toxicol. Methods 67 2013 194 202 10.1016/j.vascn.2013.01.005
31. E.K. Kano, C.H.D.R. Serra, E.E.M. Koono, S.S. Andrade, and V. Porta Determination of lamivudine in human plasma by HPLC and its use in bioequivalence studies Int. J. Pharm. 297 2005 73 79 10.1016/j.ijpharm.2005.03.002
32. ICH, Validation of a analytical procedures: text and methodology Q2(R1), Guidance, 1994, 2005, p. 17.
33. K. Berginc, S. Žakelj, L. Levstik, D. Uršič, and A. Kristl Fluorescein transport properties across artificial lipid membranes, Caco-2 cell monolayers and rat jejunum Eur. J. Pharm. Biopharm. 66 2007 281 285 10.1016/j.ejpb.2006.10.023
34. G.E. Flaten, A.B. Dhanikula, K. Luthman, and M. Brandl Drug permeability across a phospholipid vesicle based barrier: a novel approach for studying passive diffusion Eur. J. Pharm. Sci. 27 2006 80 90 10.1016/j.ejps.2005.08.007
35. M. Muendoerfer, U.F. Schaefer, P. Koenig, J.S. Walk, P. Loos, S. Balbach, and et al. Online monitoring of transepithelial electrical resistance (TEER) in an apparatus for combined dissolution and permeation testing Int. J. Pharm. 392 2010 134 140 10.1016/j.ijpharm.2010.03.046
36. M. Koljonen, K.S. Hakala, T. Ahtola-Sätilä, L. Laitinen, R. Kostiainen, T. Kotiaho, and et al. Evaluation of cocktail approach to standardise Caco-2 permeability experiments Eur. J. Pharm. Biopharm. 64 2006 379 387 10.1016/j.ejpb.2006.06.006
37. a. Zvonar, K. Berginc, a. Kristl, and M. Gašperlin Microencapsulation of self-microemulsifying system: improving solubility and permeability of furosemide Int. J. Pharm. 388 2010 151 158 10.1016/j.ijpharm.2009.12.055
38. Y. Zambito, C. Zaino, G. Uccello-Bareta, F. Balzano, and G. Di Colo Improved synthesis of quaternary ammonium-chitosan conjugates (N + -Ch) for enhanced intestinal drug permeation Eur. J. Pharm. Sci. 33 2008 343 350 10.1016/j.ejps.2008.01.004
39. P. Annaert, J.J. Tukker, J. Van Gelder, L. Naesens, E. De Clercq, G. Van Den Mooter, and et al. In vitro, ex vivo, and in situ intestinal absorption characteristics of the antiviral ester prodrug adefovir dipivoxil J. Pharm. Sci. 89 2000 1054 1062 10.1002/1520-6017(200008)89:8<1054::AID-JPS10>3.0.CO;2-5
40. J. De Souza, Z.M.F. Freitas, and S. Storpirtis Modelos in vitro para determinação da absorção de fármacos e previsão da relação dissolução/absorção Rev. Bras. Ciências Farm. 43 2007 515 527 10.1590/S1516-93322007000400004
41. S. Itagaki, Y. Otsuka, S. Kubo, H. Okumura, Y. Saito, M. Kobayashi, and et al. Intestinal uptake of nateglinide by an intestinal fluorescein transporter Biochim. Biophys. Acta - Biomembr. 1668 2005 190 194 10.1016/j.bbamem.2004.12.005
42. Y. Konishi, K. Hagiwara, and M. Shimizu Transepithelial transport of fluorescein in Caco-2 cell monolayers and use of such transport in in vitro evaluation of phenolic acid availability Biosci. Biotechnol. Biochem. 66 2002 2449 2457 10.1271/bbb.66.2449
43. K. Kuwayama, S. Miyauchi, R. Tateoka, H. Abe, and N. Kamo Fluorescein uptake by a monocarboxylic acid transporter in human intestinal Caco-2 cells Biochem. Pharmacol. 63 2002 81 88 10.1016/S0006-2952(01)00853-X
44. M. Uchida, T. Fukazawa, Y. Yamazaki, H. Hashimoto, and Y. Miyamoto A modified fast (4 days) 96-well plate Caco-2 permeability assay J. Pharmacol. Toxicol. Methods 59 2009 39 43 10.1016/j.vascn.2008.10.006
45. V.E. Thiel-Demby, J.E. Humphreys, L.A.S.J. Williams, H.M. Ellens, N. Shah, A.D. Ayrton, and et al. Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay Mol. Pharm. 6 2009 11 18 10.1021/mp800122b
46. H. Lennernäs, S. Nylander, and a.L. Ungell Jejunal permeability: a comparison between the ussing chamber technique and the Single-Pass perfusion in humans Pharm. Res. 14 1997 667 671 10.1023/A:1012121632357
47. A. Dahan, and G.L. Amidon Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs Mol. Pharm. 6 2009 19 28 10.1021/mp800088f
48. E. Watanabe, M. Takahashi, and M. Hayashi A possibility to predict the absorbability of poorly water-soluble drugs in humans based on rat intestinal permeability assessed by an in vitro chamber method Eur. J. Pharm. Biopharm. 58 2004 659 665 10.1016/j.ejpb.2004.03.029
49. Y. Masaoka, Y. Tanaka, M. Kataoka, S. Sakuma, and S. Yamashita Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract Eur. J. Pharm. Sci. 29 2006 240 250 10.1016/j.ejps.2006.06.004
50. P. Artursson, K. Palm, and K. Luthman Caco-2 monolayers in experimental and theoretical predictions of drug transport Adv. Drug Deliv. Rev. 64 2012 280 289 10.1016/j.addr.2012.09.005
51. D. Siccardi, L.E. Kandalaft, M. Gumbleton, and C. McGuigan Stereoselective and concentration-dependent polarized epithelial permeability of a series of phosphoramidate triester prodrugs of d4T: an in vitro study in Caco-2 and Madin-Darby canine kidney cell monolayers J. Pharmacol. Exp. Ther. 307 2003 1112 1119 10.1124/jpet.103.056135
52. J. De Souza, L.Z. Benet, Y. Huang, and S. Storpirtis Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers J. Pharm. Sci. 98 2009 4413 4419 10.1002/jps.21744
53. H. Yu, and P.J. Sinko Influence of the microporous substratum and hydrodynamics on resistances to drug transport in cell culture systems: calculation of intrinsic transport parameters J. Pharm. Sci. 86 1997 1448 1457 10.1021/js960524q
54. J.M. Reis, Ensaio de permeabilidade em membrana artificial paralela (PAMPA): Investigação das variáveis do ensaio para o estudo da permeabilidade de fármacos, University of São Paulo, 2013.
55. J.M. Reis, B. Sinkó, and C.H.R. Serra Parallel artificial membrane permeability assay (PAMPA) - is it better than Caco-2 for human passive permeability prediction? Mini Rev. Med. Chem. 10 2010 1071 1076
56. E. Pretorius, and P.J.D. Bouic Permeation of four oral drugs through human intestinal mucosa AAPS PharmSciTech 10 2009 270 275 10.1208/s12249-009-9207-4
57. M.A. Quevedo, and M.C. Briñón In vitro and in vivo pharmacokinetic characterization of two novel prodrugs of zidovudine Antiviral Res. 83 2009 103 111 10.1016/j.antiviral.2009.03.010
58. K.C.C. Soares, C.F. Rediguieri, J. Souza, C.H.R. Serra, B. Abrahamsson, D.W. Groot, and et al. Biowaiver monographs for immediate-release solid oral dosage forms: zidovudine (azidothymidine) J. Pharm. Sci. 102 2013 2409 2423 10.1002/jps.23624
59. C.H. dos Reis Serra, E.E. Mori Koono, E.K. Kano, S.G. Schramm, Y.P. Armando, and V. Porta Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study Clin. Ther. 30 2008 902 908 10.1016/j.clinthera.2008.05.003
60. U. Fagerholm, and H. Lennernäs Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug absorption Eur. J. Pharm. Sci. 3 1995 247 253 10.1016/0928-0987(95)00027-B
61. A.B.R. Thomson, and J.M. Dietchy The role of the unstirred water layer in intestinal permeation T.Z. Csaky, Pharmacol. Intest. Permeat. II 1984 Springer Berlin
62. P.E. Nielsen, and A. Avdeef PAMPA - a drug absorption in vitro model: 8. Apparent filter porosity and the unstirred water layer Eur. J. Pharm. Sci. 22 2004 33 41 10.1016/j.ejps.2004.02.003
63. P.V. Balimane, and P.J. Sinko Involvement of multiple transporters in the oral absorption of nucleoside analogues Adv. Drug Deliv. Rev. 39 1999 183 209 10.1016/S0169-409X(99)00026-5
64. N.a. Kasim, M. Whitehouse, C. Ramachandran, M. Bermejo, H. Lennernäs, A.S. Hussain, and et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification Mol. Pharm. 1 2004 85 96 10.1021/mp034006h
65. H. Kortejärvi, R. Shawahna, A. Koski, J. Malkki, K. Ojala, and M. Yliperttula Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs J. Pharm. Sci. 99 2010 621 625 10.1002/jps.21879
66. S. Strauch, E. Jantratid, J.B. Dressman, H.E. Junginger, S. Kopp, K.K. Midha, and et al. Biowaiver monographs for immediate release solid oral dosage forms: lamivudine J. Pharm. Sci. 100 2011 2054 2063 10.1002/jps.22449
67. A.L.L. Silva, R. Cristofoletti, S. Storpirtis, V.D. Sousa, H.E. Junginger, V.P. Shah, and et al. Biowaiver monographs for immediate-release solid oral dosage forms: stavudine J. Pharm. Sci. 101 2012 10 16 10.1002/jps.22756
68. P. Zakeri-Milani, M. Barzegar-Jalali, H. Tajerzadeh, Y. Azarmi, and H. Valizadeh Simultaneous determination of naproxen, ketoprofen and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation J. Pharm. Biomed. Anal. 39 2005 624 630 10.1016/j.jpba.2005.04.008
69. J.P. Sabo, M.J. Lamson, G. Leitz, C.L. Yong, and T.R. MacGregor Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection AAPS PharmSci 2 2002 10.1208/ps020101
70. S.K.B. Sy, R. Malmberg, A. Matsushima, E. Asin-Prieto, B. Rosenkranz, M.F. Cotton, and et al. Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model Int. J. Antimicrob. Agents 45 2015 413 419 10.1016/j.ijantimicag.2014.12.016
71. C. Zhu, L. Jiang, T.-M. Chen, and K.-K. Hwang A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential Eur. J. Med. Chem. 37 2002 399 407
72. P.V. Balimane, and S. Chong Evaluation of permeability and P-glycoprotein interactions: industry outlook Biopharm. Appl. Drug Dev. 2008 101 138 10.1007/978-0-387-72379-2
73. J.D. Irvine, L. Takahashi, K. Lockhart, J. Cheong, J.W. Tolan, H.E. Selick, and et al. MDCK (Madin - Darby Canine Kidney) cells: a tool for membrane permeability screening J. Pharm. Sci. 88 1999
74. E. Danelian, A. Karlén, R. Karlsson, S. Winiwarter, A. Hansson, S. Löfås, and et al. SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans J. Med. Chem. 43 2000 2083 2086 10.1021/jm991156g
75. P.V. Balimane, Y.-H. Han, and S. Chong Current industrial practices of assessing permeability and P-glycoprotein interaction AAPS J. 8 2006 E1 E13 10.1208/aapsj080101